



Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice

Harshini Neelakantan^a, Virginia Vance^a, Michael D. Wetzel^{b,c}, Hua-Yu Leo Wang^d, Stanton F. McHardy^d, Celeste C. Finnerty^{b,c}, Jonathan D. Hommel^e, Stanley J. Watowich^{a,*}

^a Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX 77550, USA

^b Department of Surgery, University of Texas Medical Branch, Galveston, TX 77550 USA

^c Shriners Hospitals for Children-Galveston, Galveston, TX 77550, USA

^d Department of Chemistry and Center for Innovative Drug Discovery, University of Texas at San Antonio, San Antonio, TX 78249, USA

^e Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77550, USA

ARTICLE INFO

Article history:

Received 7 September 2017

Accepted 13 November 2017

Available online 15 November 2017

Keywords:

Obesity

Therapeutics

Nicotinamide N-methyltransferase

Inhibitors

Weight loss

ABSTRACT

There is a critical need for new mechanism-of-action drugs that reduce the burden of obesity and associated chronic metabolic comorbidities. A potentially novel target to treat obesity and type 2 diabetes is nicotinamide-N-methyltransferase (NNMT), a cytosolic enzyme with newly identified roles in cellular metabolism and energy homeostasis. To validate NNMT as an anti-obesity drug target, we investigated the permeability, selectivity, mechanistic, and physiological properties of a series of small molecule NNMT inhibitors. Membrane permeability of NNMT inhibitors was characterized using parallel artificial membrane permeability and Caco-2 cell assays. Selectivity was tested against structurally-related methyltransferases and nicotinamide adenine dinucleotide (NAD⁺) salvage pathway enzymes. Effects of NNMT inhibitors on lipogenesis and intracellular levels of metabolites, including NNMT reaction product 1-methylnicotinamide (1-MNA) were evaluated in cultured adipocytes. Effects of a potent NNMT inhibitor on obesity measures and plasma lipid were assessed in diet-induced obese mice fed a high-fat diet. Methylquinolinium scaffolds with primary amine substitutions displayed high permeability from passive and active transport across membranes. Importantly, methylquinolinium analogues displayed high selectivity, not inhibiting related SAM-dependent methyltransferases or enzymes in the NAD⁺ salvage pathway. NNMT inhibitors reduced intracellular 1-MNA, increased intracellular NAD⁺ and S-(5'-adenosyl)-L-methionine (SAM), and suppressed lipogenesis in adipocytes. Treatment of diet-induced obese mice systemically with a potent NNMT inhibitor significantly reduced body weight and white adipose mass, decreased adipocyte size, and lowered plasma total cholesterol levels. Notably, administration of NNMT inhibitors did not impact total food intake nor produce any observable adverse effects. These results support development of small molecule NNMT inhibitors as therapeutics to reverse diet-induced obesity and validate NNMT as a viable target to treat obesity and related metabolic conditions. Increased flux of key cellular energy regulators, including NAD⁺ and SAM, may potentially define the therapeutic mechanism-of-action of NNMT inhibitors.

© 2017 Elsevier Inc. All rights reserved.

1. Introduction

Obesity is a major public health problem around the world that is linked to severe comorbid disease conditions, physical impairment, high mortality rates, and compromised quality of life

[1–4]. Obesity is characterized by the buildup of excessive body fat and extreme dysregulation in whole-body energy expenditure, glucose, hormone, and lipid homeostasis that typically present as adverse metabolic disorders [4,5]. Additionally, the physiological, metabolic, and psychological changes that accompany obesity are major factors in the development of type 2 diabetes (T2D), cardiovascular disease (CVD) (e.g., coronary heart disease, dyslipidemia, hypertension) [6,7], stroke, inflammation, non-alcoholic fatty

* Corresponding author.

E-mail address: watowich@xray.utmb.edu (S.J. Watowich).

liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), osteoarthritis, sleep apnea, and several obesity-linked cancers (e.g., colorectal, breast, kidney, prostate) [6,8]. Lifestyle modifications including diet and exercise may help reverse obesity and improve chronic disease biomarkers (e.g., T2D) [9], but are largely ineffective in achieving sustained weight loss and glycemic control [10]. Pharmacological treatments for obesity exist, but unfortunately most approved anti-obesity drugs have only modest efficacy and/or produce severe adverse effects (e.g., cardiovascular risks, central nervous system effects). Thus, there is a critical need for more effective pharmacological interventions that improve long-term management of obesity and its comorbidities [11].

Recently, nicotinamide-N-methyltransferase (NNMT) has emerged as a novel mechanism-of-action target in the adipose tissue to treat obesity and associated T2D [12–15]. NNMT is a cytosolic enzyme with a newly identified role in modulating cellular energy homeostasis by jointly regulating nicotinamide (NA) and S-(5'-adenosyl)-L-methionine (SAM) flux within the critical intracellular nicotinamide adenine dinucleotide (NAD⁺) salvage pathway and methionine cycle, respectively [15]. NNMT expression is upregulated in the white adipose tissue (WAT) of obese and diabetic mice [12] and has significantly higher activity in the WAT compared to its activity in the brown adipose tissue, liver, and lungs of diet-induced obese mice [16]. Furthermore, plasma levels of the NNMT reaction product 1-methylnicotinamide (1-MNA) correlate with adipose NNMT expression, individuals' body mass index (BMI), and waist circumference, suggesting the target to be clinically relevant [13,14]. Importantly, mice fed a high-fat diet and treated with antisense oligonucleotides (ASOs) that reduced adipose NNMT expression were protected from diet-induced obesity (DIO) and showed reduced adiposity compared to control animals [12].

Using structure-guided design and binding calculations, we recently generated potent small molecule NNMT inhibitors around a methylquinolinium (MQ)-scaffold [17]. In the present study, we extend these findings to show that the small molecule NNMT inhibitors are highly membrane-permeable, selective inhibitors, which reduce intracellular 1-MNA levels and prevent lipogenesis *in vitro*. These amenable properties demonstrated for the small molecules led us to conduct a proof-of-concept *in vivo* study in diet-induced obese mice to test the hypothesis that the most potent inhibitor when administered systemically, would reverse obesity by causing substantial loss of body weight and adiposity without causing any observable adverse effects.

2. Materials and methods

2.1. Chemicals

NNMT inhibitors and standards for LC/MS/MS studies were purchased from established commercial suppliers or synthesized in-house by established synthetic schemes as described previously [17]. SAM, NA, 1-MQ, 1,8-diMQ, NAD⁺, and 6-chloro nicotinamide (6-CN) were obtained from Sigma-Aldrich (St. Louis, MO, USA). 1-MNA and S-(5'-adenosyl)-L-methionine (SAH) were obtained from Cayman Chemical Company (Ann Arbor, MI, USA).

2.2. Parallel artificial membrane permeability assay (PAMPA)

Passive membrane transport properties were measured using a 96-well pre-coated PAMPA plate system with membrane pore size 0.4 μm (Gentest™, Corning; Bedford, MA, USA). Briefly, 1 mM stock solution of each compound was prepared in deionized water, diluted to a final concentration of 400 μM in PBS (Sigma Aldrich; St. Louis, MO), and placed in the plate bottom well (donor well).

After 4 h of incubation at room temperature, the sample concentration in the donor and acceptor wells were measured using a UV-Vis spectrophotometer (Beckman, DU640) set at the wavelength corresponding to the maximum absorption of each compound. Compound concentration in the donor and acceptor wells were calculated from calibration curves spanning 400 to 3.125 μM. Samples were tested in triplicates in three separate experiments.

2.3. Bi-directional permeability assay with Caco-2 cells

Compounds were tested in a Caco-2 cell bi-directional permeability assay using an established contract research organization (Cyprotex; Watertown, MA, USA). Briefly, Caco-2 cells were seeded in 96-well plates and allowed to grow in culture media for three weeks, feeding at 2-day intervals. To ensure a well-defined Caco-2 cell monolayer prior to initiation of experiments, aliquots of the cell buffers were analyzed by fluorescence to determine the transport of the impermeable dye Lucifer yellow. For apical to basolateral (A → B) and basolateral to apical (B → A) permeability, compounds were added at 10 μM concentration to the apical (A) side and basolateral (B) side, respectively, and the corresponding amount of permeation was determined by measuring compound concentration on the B or A side. The A-side buffer contained 100 μM Lucifer yellow dye, in transport buffer (1.98 g/L glucose in 10 mM HEPES, 1x Hank's balanced salt solution, pH 7.4), and the B-side buffer was transport buffer at pH 7.4. Caco-2 cells were incubated with these buffers for 2 h, and the receiver side buffer was removed for analysis by LC/MS/MS (using bucetin as an analytical internal standard). Data were expressed as permeability (P_{app}) calculated using the following formula:

$$P_{app} = \frac{dQ/dt}{c_0A}, \quad \text{where}$$

dQ/dt, rate of permeation

c_0 , initial concentration of compound
A, area of monolayer (0.11 cm²)

Efflux Ratio (R_e) was calculated using the formula:

$$R_e = \frac{P_{app}(B \rightarrow A)}{P_{app}(A \rightarrow B)}$$

2.4. MTT cell viability assay

3T3-L1 pre-adipocytes cells (catalog CL-173, American Type Culture Collection; Manassas, VA, USA) were seeded at a density of 2×10^3 cells per well in 96-well plates, cultured with standard culture media [DMEM, 4.5 g/L glucose, L-glutamine, sodium pyruvate (Mediatech Inc.; Tewksbury, MA, USA), 10% FBS (Sigma Aldrich; St. Louis, MO, USA), 1% antibiotic-antimycotic solution (Mediatech Inc.; Tewksbury, MA, USA)], and grown for 48 h until >~90% confluent. Cells were treated for 24 h with 0.1–600 μM NNMT inhibitors in cell culture media. A 24 h time point was chosen based on a previous report of using this time period for transfecting or treating 3T3-L1 cells with NNMT anti-sense oligonucleotides or a small molecule NNMT product inhibitor (1-MNA), respectively, for phenotypic measures [12]. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (ATCC; Manassas, VA, USA) was added to each well and assayed according to the manufacturer's instructions. Absorbance corresponding to the amount of formazan dye produced by treated cells was normalized to that produced by control (untreated) cells to calculate % viable cells in the treated samples.

2.5. Differentiation of 3T3-L1 pre-adipocytes

3T3-L1 pre-adipocytes cells were cultured with standard culture media (DMEM, 4.5 g/L glucose, L-glutamine, sodium pyruvate, 10% FBS, 1% antibiotic-antimycotic solution) and grown for 48 h before initiating differentiation using the manufacturer's suggested protocol and modified from previously published work [18]. Briefly, standard culture medium was supplemented with scheduled addition of adipogenic agents [3-isobutyl-1-methyl xanthine (IBMX), Sigma Aldrich; MO, USA), dexamethasone (Sigma Aldrich; MO, USA), insulin (Gibco Life Technologies Inc.; Grand Island, NY, USA)] over 10 days to promote differentiation of 3T3-L1 fibroblasts into adipocytes; a combination of 1 mM IBMX, 1 μ M dexamethasone, and 10 μ g/ml of insulin in media was added to fully confluent 3T3-L1 fibroblasts for three days (days 0–3) to initiate differentiation. At day 3, the medium was replaced with culture media supplemented with insulin (10 μ g/ml). After day 6, cells were maintained in culture media until described experiments were begun (days 8–10).

2.6. Quantitative measurement of NNMT reaction product 1-MNA in cultured cells

Cellular 1-MNA concentrations were determined using an ultra-sensitive high-resolution AB Sciex 6500 Q-trap mass spectrometer coupled to an Agilent 1260 ultra-high pressure liquid chromatography (LC/MS/MS) system. Using multiple reaction monitoring (MRM) positive ion mode, the 1-MNA NNMT reaction product was quantified from peak area ratios using AB Sciex Analyst and MultiQuant 2.1 software and the parent precursor and Q3 masses set to m/z 137.1 and 94.1, respectively. Fragment ions at m/z of 92.1 and 77.9 were additionally used for the detection and confirmation of 1-MNA, respectively. Processing of undifferentiated 3T3-L1 pre-adipocytes (day 0) and differentiated adipocytes (day 10) were optimized for recovery and reproducibility of 1-MNA levels across cultured batches of 3T3-L1 cells (~passages 7–8) and the 1-MNA levels were compared between the pre-adipocytes and adipocytes. To determine the effect of NNMT inhibitor on NNMT activity in the pre-adipocytes and differentiated adipocytes (8×10^4 cells/well seeded prior to beginning differentiation), cells were treated with 30 μ M inhibitor for 24 h. Similarly, to compare the relative effects of multiple NNMT inhibitors on NNMT activity in cultured adipocytes, differentiated adipocytes in 6-well plates were treated with 10 μ M test compound for 24 h. Following treatment, medium was replaced with 80% (v/v) methanol (cooled to -80°C) containing 500 nmol 6-chloronicotinamide (6-CN) as an internal standard (IS) to extract cellular metabolites. Adherent cells were scrapped, then centrifuged at 4°C and 13,000g for 15 min, and the resulting supernatants processed using established protocols [19]. Intracellular levels of 1-MNA and as well as the IS were determined from LC/MS/MS peak areas. Data were subsequently normalized to the IS peak area and transformed as % control values for cross-sample comparisons. The above procedure was repeated with inhibitor concentrations spanning 0.3–60 μ M for 5-amino-1MQ to determine the effective concentration (EC_{50}) required to inhibit 50% NNMT activity in cultured adipocytes. Choice of inhibitor concentrations and time period was chosen based on the results of the MTT studies.

2.7. Quantitative measurement of selected metabolites in cultured cells

The relative levels of selected metabolites (NA, SAM, SAH, NAD^+) regulated by cellular energy expenditure pathways associated with NNMT were simultaneously detected using LC/MS/MS and MRM ratios. Sample processing was performed as described above. Parent precursor masses of 124.0, 399.3, 385.1, and 665.1

Da and Q3 masses set to m/z 80.0, 250.1, 136.0, and 136.0 were used for the quantitation of NA, SAM, SAH, and NAD^+ , respectively.

2.8. Selectivity of NNMT inhibitors

Test compounds were screened in biochemical assays for activity against three structurally similar methyltransferases, including catechol-O-methyltransferase (COMT), DNA (cytosine-5)-methyltransferase 1 (DNMT1), and protein arginine methyltransferase 3 (PRMT3). Additional biochemical assays were used to test the ability of compounds to inhibit nicotinamide phosphoribosyl transferase (NAMPT) and NAD^+ -dependent protein deacetylase sirtuin 1 (SIRT1), two enzymes in the NAD^+ biosynthesis/salvage pathway. All assays were performed by Reaction Biology Corporation (RBC; Malvern, PA, USA) and complete assay details are noted below. For each test compound, IC_{50} values were calculated from dose-response curves established with 10 concentrations of a half-log dilution series. For each assay, established enzyme specific inhibitors were included as positive controls for enzyme function and assay reproducibility. IC_{50} values were determined by non-linear least-squares fitting of a 4-parameter dose-response curve to collected data points (Graphpad Prism 7.0; La Jolla, CA, USA).

2.8.1. DNMT1 activity assay

A radiometric assay was performed by RBC using 100 μ M–5 nM SAH as an inhibitor positive control. The analogues, 1,8-diMQ and 5-amino-1MQ were tested at concentrations from 200 μ M to 10 nM and 600 μ M to 10 nM, respectively. Reactions were performed with 0.001 mg/ml DNA substrate Poly(dI-dC), 1 μ M radiolabelled S-adenosyl-L-[methyl- ^3H] methionine (SAM) co-substrate, and recombinant human DNMT1 enzyme. Activity was monitored via quantification of radiolabeled reaction product DNA 5-[methyl- ^3H]-cytosine.

2.8.2. PRMT3 activity assay

A radiometric assay was performed by RBC using 100 μ M–5 nM SAH as an inhibitor positive control. The analogues, 1,8-diMQ and 5-amino-1MQ were tested at concentrations from 200 μ M to 10 nM and 600 μ M to 10 nM, respectively. Reactions were performed with 5 μ M histone H3 (histone L-arginine) substrate, 1 μ M radiolabeled S-adenosyl-L-[methyl- ^3H] methionine (SAM) co-substrate, and recombinant human PRMT3 enzyme. Activity was monitored via quantification of radiolabeled reaction product histone [methyl- ^3H]-L-arginine.

2.8.3. 3, COMT activity assay

A radiometric assay was performed by RBC using 1 μ M–50 pM tolcapone as an inhibitor positive control. The analogues, 1,8-diMQ and 5-amino-1MQ were tested at concentrations from 200 μ M to 10 nM and 600 μ M to 10 nM, respectively. Reactions were performed with 0.5 μ M catechol substrate COMT-S01, 1 μ M radiolabelled S-adenosyl-L-[methyl- ^3H] methionine (SAM) co-substrate, and recombinant human COMT enzyme. Activity was monitored via quantification of methylated catechol reaction product (guaiacol [methyl- ^3H]).

2.8.4. NAMPT activity assay

A fluorometric assay was performed by RBC using 1 μ M–50 pM FK866 as an inhibitor positive control. The analogue 5-amino-1MQ was tested at concentrations from 600 μ M to 30 nM. Reactions were performed with 2 μ M nicotinamide and 30 μ M phosphoribosyl pyrophosphate (PRPP) in the presence of 1 mM ATP and recombinant human NAMPT enzyme. Activity was monitored using fluorescence detection and quantification of the nicotinamide mononucleotide (NMN) reaction product.

2.8.5. SIRT-1 activity assay

A fluorometric assay was performed by RBC using 100 μM –5 nM suramin sodium as an inhibitor positive control. The analogue 5-amino-1MQ was tested at concentrations from 600 μM to 30 nM. Reactions were performed with 50 μM RHKKAC, a fluorogenic peptide substrate from p53 residues 379 to 382, 500 μM NAD^+ co-substrate, and recombinant human SIRT-1 (NAD^+ -dependent) enzyme. Activity was monitored by the formation of a fluorescent product (coumarin) generated by a two-step coupled reaction that involved deacetylation of substrate by SIRT-1 followed by secondary release of the fluorophore.

2.9. Efficacy of NNMT inhibitor 5-amino-1MQ in diet-induced obese (DIO) mice

17-Week old, male DIO C57Bl/6 mice that have been fed high-fat diet (HFD) for 11 weeks (starting at week 6) were purchased from Jackson Labs (Jackson Laboratory; Bar Harbour, ME, USA). Mice were initially group housed (three/cage) and allowed to acclimate to the colony environment maintained at a constant temperature (21–23 °C) and humidity (40–50%) on a 12-h light–dark cycle (lights on 0600–1800 h). Upon arrival, mice were continued to be fed HFD (Open Source Diets formula D12451 from Research Diets Inc.; New Brunswick, NJ, USA), containing 45% energy from fat. Water was available *ad libitum*. All experiments were carried out in accordance with the *Guide for the Care and Use of Laboratory Animals* [20] and with approval from the Institutional Animal Care and Use Committee at the University of Texas Medical Branch. Following acclimation for seven days, mice were single-housed and maintained on HFD for 4 additional weeks. Mice were intermittently handled, with body weights and food intake (hopper weights) measured 2–3 times per week. After being fed HFD for a total of 16 weeks (an appropriate rodent model of DIO and comparable to human obesity [21]) and reaching pre-arrival body weights (~ 38 g), mice were randomized into balanced control and treatment cohorts ($n = 9$ /cohort), with similar group average body weight and standard deviation. Mice in the vehicle cohort received three subcutaneous (SC) saline (1 ml/kg) injections/day (~ 0930 , 1330, 1730 h) and mice in the treatment cohort received three SC injections of the NNMT inhibitor 5-amino-1MQ at a dose of 20 mg/kg/injection for a total dose of ~ 34 mg/kg/day of the parent compound (calculated according to free weight) for 11 days. The dose chosen was based on an initial dose escalation study (ranging from 10 mg/kg/day to a total dose of 150 mg/kg/day) in DIO mice ($n = 2$); a total dose of 60 mg/kg/day was well tolerated with no observable adverse effects. Body weight and food intake were measured every other day. On day 12, mice were subjected to a 4 h fast period, then deeply anesthetized using isoflurane and trunk blood was collected by decapitation. Plasma was separated from every sample and the samples were submitted to Texas A&M Veterinary Medical Diagnostic Laboratory (TVMDL; College Station, TX, USA) for plasma lipid-panel measurements (total cholesterol and triglycerides). Triglycerides values were not included for analysis since the measurements were confounded by sample hemolysis that interfered with the triglyceride reagent in the assay. Epididymal fat pads (epididymal white adipose tissue; EWAT) were excised from every mouse, weighed, and fixed in 10% buffered formalin for further processing.

2.10. Histological analysis

Formalin-fixed EWAT samples were paraffin embedded, sectioned (4 μM), and stained with hematoxylin and eosin (H&E). Images were obtained at 20 \times magnification using a light microscope (Leica DM LB) and digitally photographed for automated image analysis. Images were analyzed using the “Adiposoft”

plug-in software in ImageJ (NIH) [22]. Briefly, images were converted to 8-bit images and scaled to 0.366 μm per pixel (corresponding to 20 \times magnification on the Leica microscope). Minimum and maximum diameter parameters were assigned to identify appropriate cells for the automated adipocyte area calculations, and cells along the boundary of the images were excluded from analyses. Three to five images/sample were analyzed, with automated analysis confirmed by visual inspection. Images corresponding to each sample were averaged to obtain the mean adipocyte area (μm^2) per sample and combined to calculate group mean values for control (vehicle-treated EWAT samples) and treatment (NNMT inhibitor-treated EWAT samples) cohorts.

2.11. Effect of NNMT inhibitor on adipocyte differentiation quantitated with oil red O staining

3T3-L1 cells were cultured in 60 mm diameter dishes (8.4×10^4 cells/dish) and treated with NNMT inhibitor dissolved in culture media with/without adipogenic factors (1 mM IBMX, 1 μM dexamethasone, 10 $\mu\text{g}/\text{ml}$ of insulin) during each of the scheduled medium changes during the differentiation process (described above). On day 9 post-differentiation, cells were subjected to quantitative oil red O (Thermo Fisher Scientific; Waltham, MA, USA) staining as adapted and modified from published protocols [12]. Briefly, cells were washed twice with PBS, fixed with 10% formalin for 30 min at room temperature, and stained with oil red O working solution ($\sim 0.2\%$ oil red O in 99% isopropanol) for 30 min. Cells were then washed five times or with sterile water until unincorporated oil red O stain was completely removed. Images of oil red O staining in control and inhibitor-treated cells were digitally photographed using a light microscope (Olympus BX41; Tokyo, Japan). After image capture, 2-propanol (3.5 mL) was added to each dish for 10 min to dissolve the oil red O stain and absorbance was quantified in a plate reader set at 492 nm wavelength. To ensure the absorbance from oil red O staining was within the linear detection range of the plate reader, a calibration curve was established for oil red O staining in adipocytes using a previously described protocol [23].

2.12. Statistical analysis

Statistical analysis for two-group comparisons was conducted using unpaired Student's *t*-test. A one-way analysis of variance (ANOVA) with Dunnett's posthoc test was used to compare multiple groups (different inhibitor treatments or concentration effects in cellular assessments) to controls. Daily NNMT inhibitor effects on body weight measures in DIO mice was analyzed using a repeated measures two-way ANOVA with Sidak's multiple comparison posthoc test. All statistical analyses were performed using Graphpad Prism 7.0 with an experiment-wise error rate of $\alpha = 0.05$.

3. Results

3.1. NNMT inhibitors display high membrane permeability

Compounds spanning ~ 100 -fold IC_{50} values for NNMT inhibition were selected on the basis of positional substitutions around the N-methylated quinolinium scaffold [17] to obtain an estimate of drug-like oral absorption/bioavailability properties and guide the choice of inhibitors for *in vitro* and *in vivo* phenotypic studies. Tables 1 and 2 summarize passive membrane diffusion and active transport membrane permeability, respectively, for select small molecule NNMT inhibitors for which structure activity relationships had been previously developed [17]. 1-MNA, a product inhibitor of NNMT [12,24,25] exhibited no passive permeability

Table 1
NNMT inhibitor permeability from passive transport across membranes as measured using PAMPA.

Name	IC ₅₀ (μM) ^a	Flux (cm/s)	Permeability Classification ^b
Quinoline (highly permeable) ^c	ND	33.9E-06	High permeability
1-Methylnicotinamide (1-MNA)	9.0	0	No permeability
1-Methylquinolinium (1-MQ)	12.1	0	No permeability
1,8-DiMQ	1.8	8.63702E-07	Low permeability
1,2,4,8-TetraMQ	109.2	6.98184E-07	Low permeability
5-Amino-1MQ	1.2	3.01472E-06	High permeability
3-Amino-6-fluoro-1MQ	1.2	1.07832E-06	Moderate permeability
7-Amino-1MQ	2.6	2.05476E-06	High permeability
2,3-Diamine-1MQ	2.8	3.89795E-06	High permeability

ND: Not determined; Quinoline is an NNMT substrate [25].

^a IC₅₀ values from our published SAR study [17].

^b BCS, Biopharmaceutics Classification System.

^c High membrane-permeable comparator compound [51]

Table 2
Active transport across cell membranes and drug efflux ratios for NNMT inhibitors determined using Caco-2 assay.

Name	Mean A → B Papp 10 ⁻⁶ cm/s	Mean B → A Papp 10 ⁻⁶ cm/s	Efflux Ratio (R _e)	Classification
Ranitidine ^a	0.192	1.44	11.9	Low permeability (control)
Talinolol ^a	23.5	15.7	0.673	High permeability (control)
Warfarin ^a	0.0701	5.01	73.2	High efflux (control)
1,8-DiMQ	BLQ	1.78	NC	Low permeability
5-Amino-1MQ	34.2	45.2	1.33	High permeability (no efflux)
7-Amino-1MQ	26.0	39.6	1.52	High permeability (no efflux)
2,3-Diamine-1MQ	5.27	21.2	4.03	Moderate permeability (moderate efflux)

BLQ: No peak detected in receiver side sample for A → B transport.

NC: not calculable.

^a Standard controls used in the assay based on permeability classifications.

(Table 1). Similarly, the quinolinium containing parent analogue 1-MQ also lacked passive diffusion properties (Table 1), suggesting that the lipophilicity and drug-like permeability properties of analogues within the methylquinolinium series had to be improved via chemical modification. To this end, we synthesized a number of per-methylated quinolinium analogues [17] guided by *in silico* calculation of partition coefficient (clogP) [26]. Addition of hydrophobic methyl group substitutions around the quinolinium scaffold (previously shown to negatively impact NNMT inhibitory activity) [17] only slightly improved membrane permeability via passive transport as indicated by the low, but non-zero, permeability values for 1,8-diMQ and 1,2,4,8-tetraMQ (Table 1). In contrast, positional polar amine substitutions around the quinolinium core not only improved NNMT inhibition as noted previously [17], but also enabled favorable passive and active transport across membranes (Tables 1 and 2). Specifically, 5-amino-1MQ and 7-amino-1MQ exhibited high passive and active transport across membrane, with no detectable efflux observed in the Caco-2 cell assay. In contrast, the 2,3-diamino substitution in the 1MQ scaffold (2,3-diamino-1MQ) displayed high passive permeability (Table 1), but moderate bi-directional active transport with moderate efflux ratio (Table 2). Consistent with the PAMPA measurements, the 1,8-diMQ analogue exhibited very low bi-directional transport in the Caco-2 cell assay (Table 2).

3.2. Effects of NNMT inhibitors on 3T3-L1 cell viability

The cytotoxic effects of three membrane-permeable NNMT inhibitors, 5-amino-1MQ, 7-amino-1MQ, and 2,3-diamino-1MQ were evaluated in 3T3-L1 pre-adipocytes. Treatment of cells with 10 μM 5-amino-1MQ or 7-amino-1MQ and 300 μM 2,3-diamino-1MQ for a 24 h period did not impact cell viability (Fig. 1). 5-Amino-1MQ and 7-amino-1MQ produced modest cytotoxicity relative to untreated cells ($P < .01$, treated vs. control untreated cells)

at concentrations ranging from 100 to 300 μM. All three compounds displayed ~40% cytotoxicity at the highest concentration tested ($P < .001$, 600 μM-treated cells vs. control untreated cells).

3.3. Differentiated 3T3-L1 adipocytes provide a relevant cell-based system to validate NNMT inhibitor mechanism-of-action

To determine if differentiated 3T3-L1 adipocytes could be utilized as a cell-based system for mechanism-of-action and phenotypic characterization of NNMT inhibitors, we measured the




Fig. 1. Effect of NNMT inhibitors on 3T3-L1 cell viability. Data represent average viability of 3T3-L1 cells normalized to untreated (control) cells at different concentrations of 5-amino-1MQ (open bar), 7-amino-1MQ (closed bar), and 2,3-diamino-1MQ (hatched bar) ($n = 3-6$); error bars represent standard error of the mean (SEM). Treatment of 3T3-L1 pre-adipocytes with NNMT inhibitors for 24 h did not impact cell viability up to a concentration of 100 μM. $P > .05$, not significant vs. untreated 3T3-L1 cells (0 μM). $^{**}P < .01$; $^{***}P < .001$ vs. untreated 3T3-L1 cells (0 μM) analyzed by a one-way ANOVA with Dunnett's posthoc.

expression levels of NNMT and used LC/MS/MS to assess the levels of NNMT reaction product 1-MNA in fully differentiated adipocytes (day 9–10 post-differentiation) and undifferentiated pre-adipocytes (day 0). NNMT protein expression was found to be ~37-fold higher in the adipocytes (day 9) vs pre-adipocyte ($P < .0001$, Fig. 2A). Similarly, 1-MNA levels normalized to total cellular protein were ~7.5-fold higher in adipocytes compared to pre-adipocytes ($P < .05$, pre-adipocytes vs. adipocytes, Fig. 2B), suggesting relatively higher activity of the NNMT enzyme in the fully differentiated adipocytes. NNMT inhibition using 5-amino-1MQ (30 μM concentration) in both the pre-adipocytes ($P < .01$, treated pre-adipocytes vs. untreated controls) and the adipocytes ($P < .05$, treated adipocytes vs. untreated controls) resulted in significant reduction in the intracellular levels of 1-MNA (Fig. 2C).

3.4. NNMT inhibitors decrease production of 1-MNA in differentiated adipocytes

The relative effectiveness of NNMT inhibitors to lower 1-MNA levels in the differentiated adipocytes were compared at a single concentration of 10 μM (concentration well below the cytotoxic concentration range for NNMT inhibitors). Treatment of adipocytes with membrane-permeable NNMT inhibitors for 24 h resulted in a significant reduction in cellular 1-MNA levels, relative to the levels

of 1-MNA in untreated control adipocytes ($F_{(5,6)} = 42.64$, $P < .0001$) (Fig. 2D). Dunnett's posthoc tests revealed that all membrane-permeable NNMT inhibitors tested significantly decreased 1-MNA levels in the adipocytes relative to control (5-amino-1MQ, $P < .001$; 3-amino-6-fluoro-1MQ, $P < .01$; and 2,3-diamino-1MQ, $P < .05$ vs. control untreated adipocytes, respectively). In contrast, the poorly membrane-permeable NNMT inhibitor 1,2,4,8-tetraMQ did not significantly decrease intracellular 1-MNA levels compared to untreated controls ($P > .05$, n.s.). 5-amino-1MQ, an analogue from our initial series of NNMT inhibitors with low IC_{50} value ($\text{IC}_{50} \sim 1 \mu\text{M}$ [17]), and high cell membrane permeability (Table 2), produced the greatest reduction of intracellular 1-MNA levels at a concentration of 10 μM among tested inhibitors (Fig. 2D). Based on these results, we monitored changes in intracellular 1-MNA in response to 24 h treatment with varied 5-amino-1MQ concentrations. 5-amino-1MQ showed concentration-dependent inhibition of NNMT in fully differentiated adipocytes that could be fit to a 3-parameter sigmoidal dose-response curve with a calculated $\text{EC}_{50} = 2.3 \pm 1.1 \mu\text{M}$ (Fig. 2E, 2F; goodness-of-fit $R^2 = 0.94$). At inhibitor concentrations ranging from 10 to 60 μM , the relative intracellular 1-MNA levels stabilized at ~40% the level observed for untreated adipocytes; concentrations greater than 60 μM were not tested due to known cytotoxic effects in 3T3-L1 cells (see Fig. 1).




Fig. 2. Relative NNMT protein expression and reaction product 1-MNA levels in the pre-adipocytes vs adipocytes, and the mechanistic validation of NNMT inhibitors in adipocytes. Expression levels of NNMT (normalized to β -actin) in pre-adipocytes (Day 0) and fully differentiated adipocytes (Day 9) (a). Relative levels of 1-MNA in the pre-adipocytes (closed bar) and differentiated adipocytes (checkered bar) per μg of total cellular protein (b). Effects of 5-amino-1MQ (30 μM) (open bar) treatment for 24 h on the intracellular levels of the NNMT reaction product 1-MNA in pre-adipocytes (closed bar) and differentiated adipocytes (checkered bar) (c). Relative effect of NNMT inhibitors on the intracellular levels of 1-MNA in the adipocytes (inhibition of 1-MNA compared at 10 μM concentration of each inhibitor treated for 24 h) (d). Chemical structure and activity of NNMT inhibitor 5-amino-1MQ. IC_{50} for the lead inhibitor 5-amino-1MQ value was determined using a biochemical assay [17] and EC_{50} was determined from data in Fig. 3F (e). Dose-response curve showing intracellular 1-MNA levels in adipocytes following treatment with varied 5-amino-1MQ concentrations (f). Data points represent average 1-MNA levels normalized to an internal standard and transformed to % control values \pm SD ($n = 2$ replicates per data point). The goodness-of-fit R^2 between fitted curves and data was 0.94. * $P < .05$ vs. control pre-adipocytes; ^ $P < .05$; ** $P < .01$; *** $P < .001$ vs. control adipocytes; ^ $P < .01$, vs. 5-amino-1MQ (10 μM)-treated adipocytes analyzed by Student's *t*-test or a one-way ANOVA with Dunnett's posthoc where appropriate.

3.5. NNMT inhibition increases intracellular concentrations of NAD⁺ and SAM in differentiated adipocytes

Fig. 3A outlines the major elements of the mammalian NAD⁺ salvage pathway using NA as the starting substrate [27]. Since the NNMT inhibitor 5-amino-1MQ significantly reduced intracellular 1-MNA concentrations (Fig. 2B and C), we hypothesized that NNMT inhibition in adipocytes would increase intracellular concentrations of the co-substrates NA and SAM and shunt more NA into the NAD⁺ salvage cycle. A one-way ANOVA revealed an almost significant main effect of NNMT inhibitor treatment on intracellular NAD⁺ levels ($F_{(5,6)} = 4.131, P = 0.0568$) (Fig. 3B); treatment of the adipocytes with the NNMT inhibitor 5-amino-1MQ resulted in a concentration-dependent increase in the NAD⁺ levels with concentrations in the range of 1–60 μM resulting in ~ 1.2 – 1.6 -fold increase in NAD⁺ levels relative to control adipocytes. Dunnett's posttests revealed a significant increase in NAD⁺ levels at the 10 μM inhibitor concentration ($P < .05$ vs. control; Fig. 3B). Similarly, a one-way ANOVA revealed a significant main effect of NNMT inhibition on intracellular SAM levels ($F_{(5,5)} = 7.35, P = 0.0236$) in the adipocytes (Fig. 3B). Dunnett's posttests revealed a significant increase in the intracellular SAM levels at the higher inhibitor concentration relative to control adipocytes (30 $\mu\text{M}, P < .05$; 60 $\mu\text{M}, P = 0.06$). However, no statistically significant main effect of NNMT inhibitor treatment were observed for the intracellular levels of NA ($F_{(5,6)} = 1.031, P > .05$) and ($F_{(5,6)} = 0.334, P > .05$) SAH (Fig. 3B).

3.6. NNMT inhibitors are selective and do not impact related methyltransferases or enzymes in the NAD⁺ salvage pathway

The selectivity of NNMT inhibitors was confirmed by testing against a panel of structurally similar methyltransferases and two enzymes in the NAD⁺ salvage pathway (NAMPT and SIRT1; Fig. 3). Concentrations of 1,8-diMQ and 5-amino-1MQ ranging from 10 nM to 200 or 600 μM , respectively, did not inhibit DNMT1 or PRMT3 (Fig. 4A and B). Sigmoidal dose-response curves and reliable estimates of IC₅₀ values based on non-linear least-squares fitting to the available data could not be obtained since no significant inhibition of DNMT1 and PRMT3 was observed at the tested NNMT inhibitor concentrations (Table 3). Additionally, 1,8-diMQ and 5-amino-1MQ showed little inhibition of COMT at maximal tested concentrations of 200 μM (20% inhibition) and 600 μM (10% inhibition), respectively, although no clear trend of concentration-dependent inhibition was observed. As was noted for DNMT1 and PRMT3, sigmoidal dose-response curves and reliable estimates of IC₅₀ values could not be obtained since no significant inhibition was observed at the tested NNMT inhibitor concentrations.

5-Amino-1MQ did not inhibit NAMPT up to a tested concentration of 100 μM ; reliable data could not be obtained at 5-amino-1MQ concentrations above 100 μM due to interference with the NAMPT assay readout signal (Fig. 4D, Table 3). However, when the assay was repeated with 5-amino-6-fluoro-1MQ, an analogue of 5-amino-1MQ that did not interfere with the NAMPT assay, no




Fig. 3. Effects of NNMT inhibitor on intracellular levels of NAD⁺ salvage pathways and methionine cycle metabolites. Schematic illustration of pathways regulated by NNMT, including the NAD⁺ biosynthesis salvage pathway starting from NA as a precursor that feeds into energy metabolism, methionine cycle that regulates intracellular SAM concentrations and thus cellular epigenetic modifications and polyamine flux, and clearance of NA by conversion to 1-MNA and excretory products. Pathway enzyme abbreviations include NMNAT (nicotinamide mononucleotide adenyltransferase), NAMPT (nicotinamide phosphoribosyltransferase), MTase (SAM-dependent methyltransferases), PARPs (poly-ADP-ribose polymerases), and CD38 (cluster of differentiation 38/cyclic ADP ribose hydrolase) (a). Effects of the NNMT inhibitor 5-amino-1MQ on intracellular levels of NAD⁺, NA, SAM, and SAH metabolites in differentiated adipocytes treated with concentrations 0.3–60 μM for 24 h (b). Data represent mean metabolite levels measured by LC/MS/MS in 5-amino-1MQ-treated adipocytes (open bar) normalized to control untreated adipocyte (closed bar) levels in biological duplicates (\pm SD). * $P < .05$ vs. control untreated adipocytes determined by one-way ANOVAs followed by Dunnett's posttest comparisons.




Fig. 4. Normalized response curves for NNMT inhibitors (5-amino-1MQ, open triangle; 1,8-diMQ, open square) against similar methyltransferase enzymes DNMT1 (a), PRMT3 (b), and COMT (c). Normalized response curves for NNMT inhibitor 5-amino-1MQ tested against NAD⁺ salvage pathway enzymes NAMPT (d) and SIRT1 (e). Data points represent normalized enzyme activity in the respective experiments using 10 concentrations of established enzyme-specific (positive control) and NNMT inhibitors in a 3-fold dilution series. The goodness-of-fit for the positive control inhibitors across all experiments and for 5-amino-1MQ against SIRT1 activity was >0.95. All other data points could not be used to generate reliable fitted curves and estimates of IC₅₀ values.

Table 3

Activity for NNMT inhibitors against related methyltransferases and enzymes in the NAD⁺ salvage pathway.

Enzyme	IC ₅₀ (μM)		
	Positive control	1,8-diMQ	5-Amino-1MQ
DNA (cytosine-5)-methyltransferase 1	0.28 ± 0.03 (SAH)	NI	NI
Protein arginine methyltransferase 3	6.6 ± 1.2 (SAH)	NC	NC
Catechol-O-methyltransferase	0.0009 ± 0.0001 (Tolcapone)	NC	NC
Nicotinamide phosphoribosyl transferase	0.0038 ± 0.0001 (FK866)	ND	>100 ^a
NAD ⁺ -dependent protein deacetylase sirtuin 1	4.3 ± 0.6 (Suramin)	ND	NC

NI: no inhibition.

NC: not calculable.

ND: not determined.

^a Concentrations above 100 μM could not be tested due to inference in the assay readout signal.

inhibition of NAMPT was observed with analogue concentrations between 30 and 600 μM (data not shown).

5-Amino-1MQ did not inhibit SIRT1 concentrations ranging from 10 nM to 300 μM, and minor reduction in SIRT1 activity was observed with 600 μM 5-amino-1MQ (Fig. 4E). However, sigmoidal dose-response curves and reliable estimates (i.e., R² > 0.8) of IC₅₀ values could not be obtained since no significant inhibition was observed with the tested concentrations of 5-amino-1MQ. Taken together, these results suggest high selectivity of the small molecule 5-amino-1MQ analogue at pharmacologically relevant concentrations to NNMT-inhibition.

3.7. NNMT inhibitor caused weight loss and reduced adipose tissue mass in DIO mice

Since *in vitro* studies showed 5-amino-1MQ to have high cell permeability, enzyme selectivity, and cell culture efficacy, a sub-chronic (11-day) proof-of-concept *in vivo* study was conducted to test the effect of NNMT inhibition on obesity in HFD fed mice. Three times daily systemic (SC) treatment of DIO mice with

20 mg/kg of 5-amino-1MQ produced a progressive loss of body weight over the treatment period compared to controls (Fig. 5A). A repeated-measures two-way ANOVA revealed a significant main effect of the factors treatment (F_(1,16) = 12.47, P = 0.0028), time (days) (F_(5,80) = 4.437, P = 0.0012), and a significant treatment × time interaction (F_(5,80) = 10.89, P < .0001). Sidak's multiple comparison posttests revealed significant differences in body weight between control and treated DIO mice on days 6 (P < .01), 9 (P < .0001), and 11 (P < .0001) (Fig. 5A). At the end of the 11-day treatment period, control DIO mice showed a cumulative weight gain of 0.6 ± 0.4 g (~1.4% weight gain from baseline measures), while DIO mice treated with the NNMT inhibitor showed a weight loss of 2.0 ± 0.6 g (~5.1% weight loss from baseline measures) (Fig. 5A). Food intake remained the same between the groups suggesting the weight loss effect is primarily related to altered metabolism (i.e., increased energy expenditure) (F_(1,16) = 1.101, P > .05; Fig. 5B); total cumulative food intake in control and treated DIO mice was 28.1 ± 1.2 g and 26.2 ± 1.4 g, respectively (Fig. 5B, inset). Additionally, treatment of DIO mice with the NNMT inhibitor resulted in a substantial ~35% decrease (P < .001) in the mass (Fig. 5C) and size




Fig. 5. Effects of saline or NNMT inhibitor (5-amino-1MQ, 20 mg/kg, t.i.d.) administered SC over a 11-day period in DIO mice on body weight changes from baseline (a), average food intake (g/day) and cumulative food intake across 11-days [inset] (b), epididymal fat-pad weight (c), size of the EWAT (representative images) (d), adipocyte size (μm^2) determined in mean number of 20.7 ± 1.8 (DIO, saline) and 28.6 ± 2.3 adipocytes (DIO, 5-amino-1MQ) (e), representative H&E stained images of saline- and 5-amino-1MQ-treated DIO EWAT tissue (scale bar = $200 \mu\text{m}$) (f), and total plasma cholesterol levels following a 4-h fasting period (mg/dL) (g). All data points represent the mean values in $n = 9$ mice/group \pm SEM. $^*P < .05$; $^{**}P < .01$, $^{***}P < .0001$ vs. saline-treated DIO analyzed by unpaired Student's *t*-test or a repeated measures two-way ANOVA with multiple comparisons posthoc tests where applicable.

(Fig. 5D) of the EWAT compared with the control DIO mice. Consistent with these results, histological analysis of the EWAT from treated DIO mice had $>30\%$ decrease in adipocyte size ($P < .05$; Fig. 5E and 5F) and $>40\%$ decrease in adipocyte volume (data not shown) compared to control DIO mice. Plasma lipid-profile measurements showed that the total cholesterol levels were $\sim 30\%$ lower in treated DIO mice relative to control DIO mice ($P < .05$; Fig. 5G). Total cholesterol levels at the end of our study in the control DIO mice were comparable to cholesterol levels reported by the vendor for age-matched DIO mice. In contrast, cholesterol levels in the NNMT inhibitor-treated DIO mice were similar to

cholesterol levels reported by the vendor for age-matched normal chow-fed C57Bl/6 mice (www.jax.org/jax-mice-and-services/find-and-order-jax-mice/most-popular-jax-mice-strains/dio-b6).

3.8. NNMT inhibition suppresses lipogenesis in 3T3-L1 cells

In order to determine the effect of NNMT inhibition on adipocyte differentiation and lipogenesis, lipid accumulation was determined in adipocytes following treatment of 3T3-L1 cells with the NNMT inhibitor in media containing adipogenic factors. Treatment with 5-amino-1MQ produced concentration-dependent inhibition




Fig. 6. Effects of 5-amino-1MQ on lipogenesis in differentiating 3T3-L1 cells. Representative images of culture plates (top panels) and microscopic images (20x magnification; scale bar = $50 \mu\text{m}$; bottom panels) following oil red O staining of lipid droplets in the control untreated and 5-amino-1MQ (15, 30, and $60 \mu\text{M}$)-treated adipocytes (treatment continued throughout the period of differentiation) (a). Lipid accumulation determined by quantification of oil red O staining in 5-amino-1MQ (15, 30, and $60 \mu\text{M}$)-treated adipocytes; data points represent average normalized (% untreated control) values (\pm SEM) in treated adipocyte samples ($n = 2$ replicates per experiment; experiment performed 3 times) (b). Viability of 3T3-L1 cells treated with 5-amino-1MQ (0.1– $60 \mu\text{M}$); data points represent average normalized (% untreated control) values (\pm SEM) in treated 3T3-L1 samples ($n = 3$ replicates per experiment; experiment performed 3 times). $^{***}P = 0.0001$ vs. untreated adipocytes ($0 \mu\text{M}$); $^*P < .01$ vs. untreated 3T3-L1 cells analyzed by a one-way ANOVA with Dunnett's posthoc tests (c). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

of lipid accumulation in differentiating pre-adipocytes ($F_{(3,19)} = 39.26$, $P < .0001$; Fig. 6A and B). Concentrations of 30 μM and 60 μM 5-amino-1MQ reduced lipogenesis by 50% and 70%, respectively, compared to control untreated adipocytes ($P = 0.0001$; Fig. 6B). 3T3-L1 cell viability was only slightly reduced at the highest tested concentration of 5-amino-1MQ compared to untreated cell viability ($P < .05$; Fig. 6C).

4. Discussion

Pharmacological treatment of obesity using target-based approaches to either decrease food intake or increase energy expenditure has been a major area of research in recent years [11]. Here, we demonstrated a novel pharmacological approach using small molecule inhibitors of NNMT, a target enzyme with a newly identified role in energy metabolism [15], as a potential intervention to prevent adipogenesis and reverse diet-induced obesity. We rationally developed the first series of highly membrane-permeable and selective small molecule inhibitors of NNMT with pronounced efficacy in reducing the levels of the NNMT reaction product 1-MNA in adipocytes. NNMT structure-activity relationships and physical chemical property-based analysis (e.g., logP) guided the synthesis of these membrane-permeable amino-substituted quinolinium analogues, which were validated with the PAMPA and Caco-2 cell-based empirical results, suggesting high oral absorption and bioavailability for these compounds [28]. Mechanisms of active-transport that mediate the intracellular uptake of these small molecules remain to be studied. However, organic cation transporters (OCTs) [29] may likely play role in the active transport of our charged quinolinium-containing quaternary amine NNMT inhibitors across cell membranes since OCTs have been shown to facilitate cellular uptake of several organic cationic drugs (e.g., metformin) [30,31].

Importantly, quinolinium-based NNMT inhibitors showed exceptional selectivity for NNMT with no apparent activity against either closely-related (i.e., tertiary structure rmsd $< 3 \text{ \AA}$ sequence identity $> 15\%$ relative to NNMT) human methyltransferases (e.g., COMT) or functionally distinct SAM-dependent DNA (e.g., DNMT1) and protein (e.g., PRMT3) methyltransferases with primary and tertiary structures highly similar to NNMT. Additionally, analogues containing the quinolinium scaffold lacked inhibitory activity against enzymes in the NAD^+ salvage pathway that bind nicotinamide-containing substrate, including NAMPT [27,32] and the NAD^+ -dependent SIRT1 enzyme, which deacetylates NAD^+ to produce NA, a product inhibitor of SIRT1 [33]. These results suggest that quinolinium-based NNMT inhibitors achieve selectivity by specifically interacting with the NA-binding pocket of NNMT [17], unlike several known non-selective methyltransferase inhibitors that interact with the SAM-binding pocket, which is highly conserved among SAM-dependent methyltransferases [34,35].

Membrane-permeable NNMT inhibitors reduced intracellular 1-MNA levels in a concentration-dependent manner and at pharmacologically relevant concentrations that did not impact cell viability, suggesting these small molecules interact directly with NNMT in cells. Given that NNMT has been reported to be a primary metabolic enzyme [36] and a major clearance pathway for intracellular NA [15], it is likely that these small molecules are directly and selectively inhibiting the conversion of NA to 1-MNA. We found that intracellular 1-MNA and NNMT protein expression levels were substantially higher in the fully differentiated adipocytes compared to the undifferentiated pre-adipocytes, which is consistent with the differentiation-dependent enhancement in NNMT mRNA levels and enzymatic activity reported previously in the 3T3-L1 cell lines [37]. The higher levels of 1-MNA and NNMT in adipocytes compared to pre-adipocytes may partially account for our observa-

tions that increasing concentrations (10–60 μM) of NNMT inhibitor did not completely eliminate 1-MNA in adipocytes, but did fully suppress 1-MNA accumulation in undifferentiated pre-adipocytes. In addition, the observed differential 1-MNA steady-state levels following NNMT inhibition may reflect differential transcriptional regulation of cellular metabolic pathways across the various stages of 3T3-L1 differentiation [38]; for example, aldehyde oxidase (AOX)-mediated degradation of 1-MNA may be more pronounced in pre-adipocytes compared to adipocytes, thereby synergistically reducing 1-MNA levels to a greater extent in pre-adipocytes compared to adipocytes. Further studies will examine differentiation-specific differences in the metabolic pathways that directly impact the clearance and/or shunting of NA into the NAD^+ salvage pathway.

Our observation that intracellular NA concentrations did not increase following NNMT inhibition extends previous studies that showed NA concentrations were largely unaffected following NNMT knockdown with either adenovirus [39] or anti-sense oligonucleotides (ASOs) [12]. It is possible that significant accumulation of NA in adipocytes (and other tissues) is prevented by rapid conversion of NA to NMN and subsequent NAD^+ synthesis or transport to the extracellular environment [27]. Importantly, NNMT inhibition potentiated the absolute intracellular concentrations of NAD^+ and SAM, without altering the levels of NA and SAH in the adipocytes. These co-factors are critical regulators of cellular energy metabolism, polyamine flux, epigenetic remodeling, and SIRT1 activity in the NAD^+ salvage pathway [12,27,40]. The increased levels of SAM and NAD^+ we observed in cultured adipocytes following NNMT inhibition are consistent with the upregulation of SAM and NAD^+ observed in the WAT of DIO mice treated with NNMT ASO, which correlated with increased cellular energy expenditure, reduced adiposity, and protection against diet-induced obesity [12]. In the present study, systemic treatment of DIO mice with a small molecule NNMT inhibitor caused significant loss of body weight and WAT mass, reduction in adipocyte size, and corresponding improvements in the plasma lipid profile (i.e., decreased circulating cholesterol levels). Notably, NNMT inhibition did not impact food intake in the DIO mice nor produce any overt signs of toxicity or adverse behavioral effects at the pharmacologically effective dose. Together, our observations that a small molecule NNMT inhibitor can increase NAD^+ and SAM concentrations in differentiated adipocytes and reduce adiposity in DIO mice, suggest that treatment with an NNMT inhibitor effectively reverses obesity via modulation of the NAD^+ salvage and SAM-mediated (e.g., polyamine flux) pathways to regulate energy expenditure in the adipose tissue.

A number of studies support NAD^+ regeneration as a therapeutic strategy to benefit patients with obesity [27]. For examples, natural NAD^+ precursor activators such as nicotinamide riboside (NR) administered via dietary supplements to high-fat fed mice protected against diet-induced obesity, increased energy metabolism, and improved insulin sensitivity [41]; some of these effects were shown to be mediated by NAD^+ -dependent SIRT1 activation [42]. Similarly, systemic administration of NMN improved glucose tolerance and diet- and age-related insulin resistant conditions [43,44]. However, dietary supplemental NAD^+ precursors (e.g., NR, NMN) require chronic administration and/or very high pharmacological doses to achieve physiologically beneficial enhancements in the NAD^+ levels, which potentially limit use in humans [27]. It could be predicted that combined administration of sub-maximal doses of dietary supplements and NNMT inhibitors that function as activators of NAD^+ might produce synergistic improvements in diet-induced obesity, and reduce adverse effects associated with chronic high-dose administration of dietary supplemental NAD^+ precursors. Studies testing the efficacy of NNMT inhibition on diet-induced obesity, both alone and combined with dietary agents, are currently in progress.

The present study demonstrated that NNMT inhibitor administered during adipocyte differentiation blocked the accumulation of lipid droplets, suggesting suppressed lipogenesis and programmed development of mature adipocytes from pre-adipocyte 3T3-L1 precursor cells (i.e., “adipogenesis”). Since 24 h of treatment of adipocytes with an NNMT inhibitor increased intracellular levels of SAM and NAD⁺, it is likely that prolonged exposures to NNMT inhibitor during differentiation may have resulted in significantly enhanced intracellular flux of SAM and NAD⁺. Increased absolute concentrations of intracellular NAD⁺ links with activation of NAD⁺-dependent histone deacetylases (e.g., sirtuins) that also mediate epigenetic regulation of gene expression [40] and adipocyte physiology [45]. Similarly, increased intracellular concentrations of SAM, a universal substrate for SAM-dependent histone methyltransferases, could have profound influence on cellular epigenetic modifications, including transcriptional regulation and the expression of genes that regulate adipogenesis and/or thermogenesis promoting browning of adipocytes (e.g., PPAR γ , PRDM16, UCP1, Wnt) [46–48]. NNMT protein expression is relatively lower in the murine brown adipose tissue (BAT) compared to the WAT [37] and *nmmt* (a WAT-selective gene [49,50]) gene expression has been reported to be lower in the BAT of HFD fed mice compared to normal chow-fed mice [49]. Furthermore, NNMT activity is significantly higher in the white fat compared to brown adipose tissue and the other organs (e.g., liver, lungs) in DIO mice [16]. Hence, treatment with an NNMT inhibitor in DIO mice may less likely impact BAT or other tissue NNMT activity, but could be speculated to modulate thermogenic/adipogenic genes in the WAT. Future studies will validate *in vivo* modulation of WAT NAD⁺/SAM and delineate NAD⁺- and SAM-mediated epigenetic mechanisms that may underlie gene regulation in the presence of NNMT inhibitors.

The current study provides conclusive evidence for the use of small molecule, “drug-like” NNMT inhibitors as a viable therapeutic approach to manage diet-induced obesity and related metabolic comorbidities. Our novel NNMT inhibitors display excellent physical chemical properties (e.g., membrane permeability), selectivity, and cellular inhibitory activity against NNMT, concomitantly enhancing the levels of the co-factors SAM and NAD⁺ that independently regulate cellular energy metabolism and epigenetic modifications. Importantly, treatment of DIO mice with our NNMT inhibitors did not impact food intake, but produced marked reductions in body weight, WAT mass, adipocyte size, and cholesterol levels with negligible toxicity or observable adverse effects. Future studies will be focused on optimizing the MQ-scaffold lead series to generate more potent NNMT inhibitors with significantly improved “drug-like” ADME profile. Orally bioavailable lead candidates will be tested in a comprehensive dose-ranging study to confirm efficacy on obesity and co-morbid endpoints.

Acknowledgements

We thank Dr. William Russell (Director, Mass Spectrometry Facility, Department of Biochemistry and Molecular Biology, UTMB) for his assistance in optimizing and running all LC/MS/MS assessments. We thank Dr. Robert Cox and Sam Jacob of the Histopathology Research Laboratory at Shriners Hospital for Children, Galveston for their support in histological processing and light microscopic analysis of the EWAT tissue samples (grant #84060, PI: Dr. Hal Hawkins). We thank Catherine Sampson for her assistance with the mouse blood collection and epididymis fat-pad isolation procedures. This work was supported by the Department of Defense Peer Reviewed Medical Research Program grant PR141776 (S.J.W.), University of Texas Medical Branch Technology Commercialization Award (S.J.W.), and NIH grant R01GM112936 (C.C.F.).

Conflict of interest

The authors declare no conflict of interest.

References

- [1] R.L. Kolotkin, K. Meter, G.R. Williams, Quality of life and obesity, *Obes. Rev.* 2 (4) (2001) 219–229.
- [2] Y.C. Wang, K. McPherson, T. Marsh, S.L. Gortmaker, M. Brown, Health and economic burden of the projected obesity trends in the USA and the UK, *Lancet* 378 (9793) (2011) 815–825.
- [3] K.M. Flegal, B.K. Kit, H. Orpana, B.I. Graubard, Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis, *JAMA* 309 (1) (2013) 71–82.
- [4] P. Gonzalez-Muniesa, M.A. Martinez-Gonzalez, F.B. Hu, J.P. Despres, Y. Matsuzawa, R.J.F. Loos, L.A. Moreno, G.A. Bray, J.A. Martinez, *Obesity, Nat. Rev. Dis. Primers* 3 (2017) 17034.
- [5] T. Caputo, F. Gilardi, B. Desvergne, From chronic overnutrition to metaflammation and insulin resistance: adipose tissue and liver contributions, *FEBS Lett.* (2017).
- [6] M.D. Jensen, D.H. Ryan, C.M. Apovian, J.D. Ard, A.G. Comuzzie, K.A. Donato, F.B. Hu, V.S. Hubbard, J.M. Jakicic, R.F. Kushner, C.M. Loria, B.E. Millen, C.A. Nonas, F. X. Pi-Sunyer, J. Stevens, V.J. Stevens, T.A. Wadden, B.M. Wolfe, S.Z. Yanovski/American College of Cardiology/American Heart Association Task Force on Practice, S. Obesity, 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society, *J. Am. Coll. Cardiol.* 63 (25 Pt B) (2014) 2985–3023.
- [7] P. Zimmet, K.G. Alberti, J. Shaw, Global and societal implications of the diabetes epidemic, *Nature* 414 (6865) (2001) 782–787.
- [8] E.E. Calle, C. Rodriguez, K. Walker-Thurmond, M.J. Thun, Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults, *N. Engl. J. Med.* 348 (17) (2003) 1625–1638.
- [9] S.R. Colberg, R.J. Sigal, Prescribing exercise for individuals with type 2 diabetes: recommendations and precautions, *Phys. Sportsmed.* 39 (2) (2011) 13–26.
- [10] A. Fildes, J. Charlton, C. Rudisill, P. Littlejohns, A.T. Prevost, M.C. Gulliford, Probability of an obese person attaining normal body weight: cohort study using electronic health records, *Am. J. Public Health* 105 (9) (2015) e54–e59.
- [11] C. Martinussen, K.N. Bojsen-Moller, M.S. Svane, T.F. Dejgaard, S. Madsbad, Emerging drugs for the treatment of obesity, *Expert. Opin. Emerg. Drugs* 22 (1) (2017) 87–99.
- [12] D. Kraus, Q. Yang, D. Kong, A.S. Banks, L. Zhang, J.T. Rodgers, E. Pirinen, T.C. Pulinilkunnil, F. Gong, Y.C. Wang, Y. Cen, A.A. Sauve, J.M. Asara, O.D. Peroni, B.P. Monia, S. Bhanot, L. Alhonen, P. Puigserver, B.B. Kahn, Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity, *Nature* 508 (7495) (2014) 258–262.
- [13] A. Kannt, A. Pfenninger, L. Teichert, A. Tonjes, A. Dietrich, M.R. Schon, N. Klötting, M. Bluher, Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance, *Diabetologia* 58 (4) (2015) 799–808.
- [14] M. Liu, L. Li, J. Chu, B. Zhu, Q. Zhang, X. Yin, W. Jiang, G. Dai, W. Ju, Z. Wang, Q. Yang, Z. Fang, Serum N(1)-methylnicotinamide is associated with obesity and diabetes in Chinese, *J. Clin. Endocrinol. Metab.* 100 (8) (2015) 3112–3117.
- [15] P. Pissios, Nicotinamide N-methyltransferase: more than a vitamin B3 clearance enzyme, *Trends Endocrinol. Metab.* 28 (5) (2017) 340–353.
- [16] B. Rudolph, B. Zapp, N.A. Kraus, F. Ehebauer, B. Kraus, D. Kraus, Body weight predicts Nicotinamide N-Methyltransferase activity in mouse fat, *Endocr. Res.* (2017) 1–9.
- [17] H. Neelakantan, H.Y. Wang, V. Vance, J.D. Hommel, S.F. McHardy, S.J. Watowich, Structure-activity relationship for small molecule inhibitors of nicotinamide N-methyltransferase, *J. Med. Chem.* 60 (12) (2017) 5015–5028.
- [18] Q.G. Zhou, X. Peng, L.L. Hu, D. Xie, M. Zhou, F.F. Hou, Advanced oxidation protein products inhibit differentiation and activate inflammation in 3T3-L1 preadipocytes, *J. Cell. Physiol.* 225 (1) (2010) 42–51.
- [19] M. Yuan, S.B. Breitkopf, X. Yang, J.M. Asara, A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue, *Nat. Protoc.* 7 (5) (2012) 872–881.
- [20] (U.S.) *IoLARGuide for the Care and Use of Laboratory Animals*, 8th ed., National Academies Press, Washington, DC, USA 2011.
- [21] C.Y. Wang, J.K. Liao, A mouse model of diet-induced obesity and insulin resistance, *Methods Mol. Biol.* 821 (2012) 421–433.
- [22] M. Galarraga, J. Campion, A. Munoz-Barrutia, N. Boque, H. Moreno, J.A. Martinez, F. Milagro, C. Ortiz-de-Solorzano, Adiposoft: automated software for the analysis of white adipose tissue cellularity in histological sections, *J. Lipid Res.* 53 (12) (2012) 2791–2796.
- [23] N.A. Kraus, F. Ehebauer, B. Zapp, B. Rudolph, B.J. Kraus, D. Kraus, Quantitative assessment of adipocyte differentiation in cell culture, *Adipocyte* 5 (4) (2016) 351–358.
- [24] S. Aksoy, C.L. Szumlanski, R.M. Weinshilboum, Human liver nicotinamide N-methyltransferase Cdna Cloning, expression, and biochemical characterization, *J. Biol. Chem.* 269 (20) (1994) 14835–14840.

- [25] H. Neelakantan, V. Vance, H.L. Wang, S.F. McHardy, S.J. Watowich, Noncoupled fluorescent assay for direct real-time monitoring of nicotinamide N-methyltransferase activity, *Biochemistry* 56 (6) (2017) 824–832.
- [26] M.M. Hann, G.M. Keseru, Finding the sweet spot: the role of nature and nurture in medicinal chemistry, *Nat Rev Drug Discov* 11 (5) (2012) 355–365.
- [27] C. Canto, K.J. Menzies, J. Auwerx, NAD(+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus, *Cell. Metab.* 22 (1) (2015) 31–53.
- [28] J. Ruell, Membrane-based drug assays, *Mod. Drug Disc.* (2003) 28–30.
- [29] T.K. Han, R.S. Everett, W.R. Proctor, C.M. Ng, C.L. Costales, K.L. Brouwer, D.R. Thakker, Organic cation transporter 1 (OCT1/mOct1) is localized in the apical membrane of Caco-2 cell monolayers and enterocytes, *Mol. Pharmacol.* 84 (2) (2013) 182–189.
- [30] J.M. Moreno-Navarrete, F.J. Ortega, J.I. Rodriguez-Hermosa, M. Sabater, G. Pardo, W. Ricart, J.M. Fernandez-Real, OCT1 Expression in adipocytes could contribute to increased metformin action in obese subjects, *Diabetes* 60 (1) (2011) 168–176.
- [31] H. Motohashi, K. Inui, Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney, *AAPS J.* 15 (2) (2013) 581–588.
- [32] E.S. Burgos, M.C. Ho, S.C. Almo, V.L. Schramm, A phosphoenzyme mimic, overlapping catalytic sites and reaction coordinate motion for human NAMPT, *Proc. Natl. Acad. Sci. U.S.A.* 106 (33) (2009) 13748–13753.
- [33] S. Imai, The NAD World: a new systemic regulatory network for metabolism and aging—Sirt1, systemic NAD biosynthesis, and their importance, *Cell Biochem. Biophys.* 53 (2) (2009) 65–74.
- [34] R.A. Copeland, M.E. Solomon, V.M. Richon, Protein methyltransferases as a target class for drug discovery, *Nat. Rev. Drug Discov.* 8 (9) (2009) 724–732.
- [35] J.L. Martin, F.M. McMillan, SAM (dependent) I AM: the S-adenosylmethionine-dependent methyltransferase fold, *Curr. Opin. Struct. Biol.* 12 (6) (2002) 783–793.
- [36] T.A. Alston, R.H. Abeles, Substrate specificity of nicotinamide methyltransferase isolated from porcine liver, *Arch. Biochem. Biophys.* 260 (2) (1988) 601–608.
- [37] M. Riederer, W. Erwa, R. Zimmermann, S. Frank, R. Zechner, Adipose tissue as a source of nicotinamide N-methyltransferase and homocysteine, *Atherosclerosis* 204 (2) (2009) 412–417.
- [38] H. Hackl, T.R. Burkard, A. Sturn, R. Rubio, A. Schleiffer, S. Tian, J. Quackenbush, F. Eisenhaber, Z. Trajanoski, Molecular processes during fat cell development revealed by gene expression profiling and functional annotation, *Genome Biol.* 6 (13) (2005) R108.
- [39] S. Hong, J.M. Moreno-Navarrete, X. Wei, Y. Kikukawa, I. Tzameli, D. Prasad, Y. Lee, J.M. Asara, J.M. Fernandez-Real, E. Maratos-Flier, P. Pissios, Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization, *Nat. Med.* 21 (8) (2015) 887–894.
- [40] R. Janke, A.E. Dodson, J. Rine, Metabolism and epigenetics, *Annu. Rev. Cell Dev. Biol.* 31 (2015) 473–496.
- [41] C. Canto, R.H. Houtkooper, E. Pirinen, D.Y. Youn, M.H. Oosterveer, Y. Cen, P.J. Fernandez-Marcos, H. Yamamoto, P.A. Andreux, P. Cettour-Rose, K. Gademann, C. Rinsch, K. Schoonjans, A.A. Sauve, J. Auwerx, The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity, *Cell. Metab.* 15 (6) (2012) 838–847.
- [42] S. Imai, W. Kiess, Therapeutic potential of SIRT1 and NAMPT-mediated NAD biosynthesis in type 2 diabetes, *Front. Biosci. (Landmark Ed)* 14 (2009) 2983–2995.
- [43] K.M. Ramsey, K.F. Mills, A. Satoh, S. Imai, Age-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice, *Aging Cell* 7 (1) (2008) 78–88.
- [44] J. Yoshino, K.F. Mills, M.J. Yoon, S. Imai, Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice, *Cell. Metab.* 14 (4) (2011) 528–536.
- [45] K.L. Stromsdorfer, S. Yamaguchi, M.J. Yoon, A.C. Moseley, M.P. Franczyk, S.C. Kelly, N. Qi, S. Imai, J. Yoshino, NAMPT-mediated NAD(+) biosynthesis in adipocytes regulates adipose tissue function and multi-organ insulin sensitivity in mice, *Cell Rep.* 16 (7) (2016) 1851–1860.
- [46] J.E. Lee, K. Ge, Transcriptional and epigenetic regulation of PPARgamma expression during adipogenesis, *Cell. Biosci.* 4 (2014) 29.
- [47] M. Okamura, T. Inagaki, T. Tanaka, J. Sakai, Role of histone methylation and demethylation in adipogenesis and obesity, *Organogenesis* 6 (1) (2010) 24–32.
- [48] K.A. Lo, P.Y. Ng, Z. Kabiri, D. Virshup, L. Sun, Wnt inhibition enhances browning of mouse primary white adipocytes, *Adipocyte* 5 (2) (2016) 224–231.
- [49] C.M. Hung, C.M. Calejman, J. Sanchez-Gurmaches, H. Li, C.B. Clish, S. Hettmer, A.J. Wagers, D.A. Guertin, Rictor/mTORC2 loss in the Myf5 lineage reprograms brown fat metabolism and protects mice against obesity and metabolic disease, *Cell Rep.* 8 (1) (2014) 256–271.
- [50] N.J. Song, S. Choi, P. Rajbhandari, S.H. Chang, S. Kim, L. Vergnes, S.M. Kwon, J.H. Yoon, S. Lee, J.M. Ku, J.S. Lee, K. Reue, S.H. Koo, P. Tontonoz, K.W. Park, Prdm4 induction by the small molecule butein promotes white adipose tissue browning, *Nat. Chem. Biol.* 12 (7) (2016) 479–481.
- [51] V.S. Gopinath, M. Rao, R. Shivahare, P. Vishwakarma, S. Ghose, A. Pradhan, R. Hindupur, K.D. Sarma, S. Gupta, S.K. Puri, D. Launay, D. Martin, Design, synthesis ADME characterization and antileishmanial evaluation of novel substituted quinoline analogs, *Bioorg. Med. Chem. Lett.* 24 (9) (2014) 2046–2052.